{"id":"1fc7753e-6b77-5a56-9fe1-71552d4a0e69","stable_key":"649e861b-265a-5912-bc36-3a73e53ef892:l-serine-hsan-trial-lipids","predicate":"reduces","statement":"In the randomized HSAN1 trial, oral L-serine reduced deoxysphinganine by 59% versus an 11% increase with placebo after one year.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"6af11197-27c8-52b7-8466-e04daf48b5d2","mechanism_event_label":"Changing substrate supply changed the abnormal lipid product in this inherited disorder.","subject":{"id":"c882cd0b-9d83-5b07-bd1c-fe4d45657dcb","slug":"l-serine","display_name":"L-Serine","entity_type_key":"small_molecule"},"object":{"id":"4d9df16d-24fa-5dc5-ab2a-2369a6a0399d","slug":"1-deoxysphingolipids","display_name":"1-Deoxysphingolipids","entity_type_key":"lipid"},"evidence_count":1,"mechanism_event":{"id":"6af11197-27c8-52b7-8466-e04daf48b5d2","stable_key":"649e861b-265a-5912-bc36-3a73e53ef892:l-serine-hsan-trial-lipids-event","event_type":"observed_relationship","label":"Changing substrate supply changed the abnormal lipid product in this inherited disorder.","description":"In the randomized HSAN1 trial, oral L-serine reduced deoxysphinganine by 59% versus an 11% increase with placebo after one year.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c882cd0b-9d83-5b07-bd1c-fe4d45657dcb","slug":"l-serine","display_name":"L-Serine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"4d9df16d-24fa-5dc5-ab2a-2369a6a0399d","slug":"1-deoxysphingolipids","display_name":"1-Deoxysphingolipids","entity_type_key":"lipid"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"18 randomized adults; 16 completed; 400 mg/kg/day versus placebo for one year followed by open-label treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"High-dose disease-specific research regimen, not a general supplement recommendation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Serine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"l-serine","display_name":"L-Serine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Changing substrate supply changed the abnormal lipid product in this inherited disorder.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. · 2019 · https://pubmed.ncbi.nlm.nih.gov/30626650/ · DOI 10.1212/WNL.0000000000006811","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"dd2e880a-d0ad-5ffe-ab02-eaf5d35172b0","evidence_kind":"source_excerpt","locator":"Lines 294-300","start_line":294,"end_line":300,"excerpt":"## l-serine-hsan-trial-lipids\nChanging substrate supply changed the abnormal lipid product in this inherited disorder.\nIn the randomized HSAN1 trial, oral L-serine reduced deoxysphinganine by 59% versus an 11% increase with placebo after one year.\nModel: 18 randomized adults; 16 completed; 400 mg/kg/day versus placebo for one year followed by open-label treatment.\nLimitations: High-dose disease-specific research regimen, not a general supplement recommendation.\nEvidence access: Primary abstract\nRandomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. · 2019 · https://pubmed.ncbi.nlm.nih.gov/30626650/ · DOI 10.1212/WNL.0000000000006811","model_system":"18 randomized adults; 16 completed; 400 mg/kg/day versus placebo for one year followed by open-label treatment.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"70bcf57a-36bb-563f-9073-2d616e5f155a","stable_key":"import-649e861b-265a-5912-bc36-3a73e53ef892","title":"L-Serine: synthesis, one-carbon metabolism, lipids and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"22a750ce2b94f8607268c58322c48c4f0468f403b72a4008307538a6e5ff86d5","revision_id":"c1d6a7e1-9558-5bc6-9e3b-7080c26d3dbc","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}